ASSYSt SIGNED
A reliable CXCL4 biomarker assay to improve diagnosis and treatment of Systemic Sclerosis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ASSYSt project word cloud
Explore the words cloud of the ASSYSt project. It provides you a very rough idea of what is the project "ASSYSt" about.
Project "ASSYSt" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2017-PoC |
| Funding Scheme | ERC-POC |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-08-01 to 2020-01-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITAIR MEDISCH CENTRUM UTRECHT | NL (UTRECHT) | coordinator | 150˙000.00 |
Map
Project objective
Systemic Sclerosis (SSc, scleroderma) is a complex autoimmune disorder of unclear aetiology, culminating in excessive extracellular matrix deposition (fibrosis/tissue scarring) in skin and internal organs (e.g. joints, heart, lung, gastrointestinal tract and kidneys). More than half of the patients will ultimately die as a result of organ complications. The medical need is exacerbated by the lack of curative treatments and the lack of specific and sensitive molecular markers to facilitate reliable diagnosis and prognosis.
My team has recently demonstrated, through research funded by the ERC Starting Grant CIRCUMVENT, that the chemokine CXCL4 is a central player in the pathogenesis of SSc. Our results suggest that CXCL4 has great potential as 1) a biomarker to assist early diagnosis, 2) a biomarker to predict SSc disease course, and 3) a therapeutic target for the treatment or prevention of fibrosis in patients with SSc. Currently, a robust, accessible, reliable, cheap and fast assay to determine CXCL4 levels for clinical use is lacking. This prohibits the use of CXCL4 to predict clinical and treatment outcome and complicates the large-scale replication experiments across multiple labs and cohorts that are necessary to validate the diagnostic value of CXCL4.
Therefore, we argue that a reliable in vitro assay measuring circulating CXCL4 levels is highly needed and can be deployed as a research support tool to accelerate the implementation of clinical strategies based on CXCL4 and a clinical decision support tool in SSc to complement current diagnostic protocols. ASSYSt will focus on 1) the development of a reliable assay to adequately determine circulating CXCL4 levels irrespective of sample collection and storage conditions, 2) assessing the market potential of each of the applications listed above, and 3) defining a strong business strategy to guide route to market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ASSYST" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ASSYST" are provided by the European Opendata Portal: CORDIS opendata.